A Shot Every Two Weeks Instead of Weekly: New GLP-1 Drug Shows Strong Trial Results A new GLP-1 receptor agonist that requires only one injection every two weeks rather than the weekly shots required by Ozempic, Wegovy, and Mounjaro has shown strong results in a Phase 2b clinical trial, with meaningful reductions in blood sugar levels and body weight in adults with type 2 diabetes
Introduction to Cognitive Enhancement Cognitive enhancement protocols are designed to improve brain performance through targeted support of energy production, neurotransmission, and neural plasticity
Hypertension 37 , 350356 (2001)
While interest is understandable, clinical evidence, safety data, and regulatory approval matter
Depletion of butyrate-producing clostridia from the gut microbiota drives an aerobic luminal expansion of salmonella
Mining of social media data Social media platforms such as Twitter and Facebook have become valuable data sources for sentiment analysis